Jong-Seok Lee

1993–2026 年に発表

別表記
Jong Seok Lee · Jong‐Seok Lee
458
論文数
50,957
被引用数
97
h 指数
295
i10 指数

被引用数

Jong-Seok Lee の年別被引用数1971 年: 被引用 1 件1975 年: 被引用 1 件1986 年: 被引用 1 件1995 年: 被引用 4 件1996 年: 被引用 9 件1997 年: 被引用 3 件1998 年: 被引用 7 件1999 年: 被引用 8 件2000 年: 被引用 12 件2001 年: 被引用 17 件2002 年: 被引用 23 件2003 年: 被引用 22 件2004 年: 被引用 21 件2005 年: 被引用 37 件2006 年: 被引用 74 件2007 年: 被引用 64 件2008 年: 被引用 79 件2009 年: 被引用 92 件2010 年: 被引用 99 件2011 年: 被引用 125 件2012 年: 被引用 205 件2013 年: 被引用 280 件2014 年: 被引用 305 件2015 年: 被引用 390 件2016 年: 被引用 661 件2017 年: 被引用 838 件2018 年: 被引用 1,003 件2019 年: 被引用 2,490 件2020 年: 被引用 2,844 件2021 年: 被引用 2,732 件2022 年: 被引用 2,403 件2023 年: 被引用 2,061 件2024 年: 被引用 3,037 件2025 年: 被引用 1,986 件2026 年: 被引用 215 件1972〜1974 年は被引用が無いため表示していません1976〜1985 年は被引用が無いため表示していません1987〜1994 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 5,721 件、この内訳の 19.3%アメリカ合衆国: 引用元論文 5,503 件、この内訳の 18.6%イギリス: 引用元論文 1,357 件、この内訳の 4.6%韓国: 引用元論文 1,348 件、この内訳の 4.6%日本: 引用元論文 1,344 件、この内訳の 4.5%イタリア: 引用元論文 1,291 件、この内訳の 4.4%フランス: 引用元論文 1,138 件、この内訳の 3.8%ドイツ: 引用元論文 1,056 件、この内訳の 3.6%スペイン: 引用元論文 966 件、この内訳の 3.3%インド: 引用元論文 823 件、この内訳の 2.8%カナダ: 引用元論文 798 件、この内訳の 2.7%オーストラリア: 引用元論文 694 件、この内訳の 2.3%
0%19.3%その他 25.5%

分野

  • Medicine53.3%
  • Computer Science12.8%
  • Neuroscience9.4%
  • Psychology8%
  • Biochemistry, Genetics and Molecular Biology7.4%
  • Immunology and Microbiology2.6%
  • その他6.5%

トピック

  • Cancer Immunotherapy and Biomarkers10%
  • Lung Cancer Treatments and Mutations6.8%
  • Emotion and Mood Recognition4.7%
  • EEG and Brain-Computer Interfaces4.6%
  • Lung Cancer Research Studies4.3%
  • Lung Cancer Diagnosis and Treatment2.8%
  • その他66.8%

共著者

全論文

検索で開く
  1. DEAP: A Database for Emotion Analysis ;Using Physiological Signals

    著者: , , , , , , , , - IEEE Transactions on Affective Computing, IEEE Trans. Affect. Comput. 2011 被引用: 4,847

  2. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 被引用: 6,228

  3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 4,780

  4. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2022 被引用: 744

  5. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 482

  6. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 824

  7. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 3,137

  8. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 294

  9. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patricia Lorenzini, Meena Thayu, Roland E. Knoblauch, Byoung Chul Cho - Journal of Clinical Oncology 2021 被引用: 632

  10. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 381

  11. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Igor Bondarenko, Yuanbin Chen, Andrzej Każarnowicz, Luis Paz‐Ares, Mustafa Özgüroğlu, Nikolay Conev, Maximilian J. Hochmair, Otto C. Burghuber, Libor Havel, İrfan Çiçin, György Losonczy, В. Моисеенко, Mustafa Erman, Dariusz M. Kowalski, Marek Z. Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Niels Reinmuth, Jun Ho Ji, Maria Amelia Insa Molla, Grygorii Ursol, Anne C. Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Francesco Verderame, Katsuyuki Hotta, Sang‐We Kim, Alexey Smolin, Tuncay Göksel, Shaker R. Dakhil, Jaromı́r Roubec, Krisztina Bogos, Marina Chiara Garassino, Robin Cornelissen, Jong-Seok Lee, M.R. García Campelo, Marta López Brea, Ahmet Alacacıoğlu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, A Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong‐Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, M. Majem Tarruella, David R. Spigel, Krassimir Koynov, Milada Zemanová, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Sławomir Mańdziuk ほか 153 名 - The Lancet Oncology 2020 被引用: 687

  12. Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 976

  13. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 被引用: 375

  14. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 282

  15. Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 382

  16. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 322

  17. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 508

  18. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

    著者: , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2022 被引用: 154

  19. NTIRE 2018 Challenge on Single Image Super-Resolution: Methods and Results

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tak-Wai Hui, Chao Dong, Liang Lin, Chen Change Loy, Park Dongwon, Kwanyoung Kim, Se Young Chun, Kai Zhang, Pengjv Liu, Wangmeng Zuo, Shi Guo, Jiye Liu, Jinchang Xu, YI-JIAO LIU, Fengye Xiong, Yuan Dong, Hongliang Bai, Alexandru Damian, Nikhil Ravi, Sachit Menon, Cynthia Rudin, Junghoon Seo, Taegyun Jeon, Jamyoung Koo, Seunghyun Jeon, Soo Ye Kim, Jae-Seok Choi, Sehwan Ki, Soomin Seo, Hyeonjun Sim, Saehun Kim, Munchurl Kim, Rong Chen, Kun Zeng, Jinkang Guo, Yanyun Qu, Cuihua Li, Namhyuk Ahn, Byungkon Kang, Kyung-Ah Sohn, Yuan Yuan, Jiawei Zhang, Jiahao Pang, Xiangyu Xu, Yan Zhao, Wei Deng, Sibt ul Hussain, Muneeb Aadil, Rafia Rahim, Xiaowang Cai, Fang Huang, Yueshu Xu, Pablo Navarrete Michelini, Dan Zhu, Hanwen Liu, Jun-Hyuk Kim, Jong‐Seok Lee, Yi‐Wen Huang, Ming Qiu, Liting Jing, Jiehang Zeng, Ying Wang, Manoj Sharma, Rudrabha Mukhopadhyay, Avinash Upadhyay, Sriharsha Koundinya, Ankit Shukla, Santanu Chaudhury, Zhe Zhang, Yu Hen Hu ほか 1 名 - IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW), CVPR Workshops 2018 被引用: 372

  20. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 397

  21. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Moon‐Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh - Journal of Clinical Oncology 2021 被引用: 355

  22. Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

    著者: , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2011 被引用: 1,235

  23. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 413

  24. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 267